background
human
metapneumoviru
hmpv
newli
identifi
pulmonari
pathogen
caus
fatal
lower
respiratori
tract
diseas
lrd
hematopoiet
cell
transplant
hct
recipi
littl
known
progress
rate
upper
respiratori
tract
infect
uri
lrd
risk
factor
associ
progress
method
total
hct
recipi
receiv
transplant
hmpv
detect
nasopharyng
bronchoalveolar
lavag
lung
biopsi
sampl
realtim
revers
transcript
polymeras
chain
reaction
retrospect
analyz
result
case
identifi
decemb
may
among
hct
patient
uri
alon
lrd
respect
among
patient
lrd
patient
progress
uri
lrd
median
day
rang
day
probabl
progress
lrd
within
day
uri
cox
regress
analysi
steroid
use
mgkg
prior
uri
diagnosi
hazard
ratio
hr
p
low
lymphocyt
count
hr
p
earli
onset
hmpv
infect
hct
day
hct
hr
p
associ
higher
progress
lrd
median
viral
load
nasal
wash
sampl
copiesml
rang
correl
viral
load
progress
conclus
progress
uri
lrd
occur
hct
recipi
risk
factor
system
corticosteroid
use
low
lymphocyt
count
studi
need
defin
role
viral
load
pathogenesi
progress
diseas
human
metapneumoviru
hmpv
newli
recogn
respiratori
pathogen
first
identifi
structur
similar
respiratori
syncyti
viru
rsv
serolog
epidemiolog
show
exposur
adulthood
hmpv
infect
occur
approxim
hematopoiet
cell
transplant
hct
recipi
caus
sever
sometim
fatal
lower
respiratori
tract
diseas
lrd
mortal
rate
hmpv
lrd
patient
hematolog
malign
hct
recipi
rang
date
studi
hct
recipi
small
focus
lrd
characterist
outcom
minim
data
exist
time
proport
risk
factor
progress
upper
respiratori
tract
infect
uri
lrd
data
critic
design
clinic
trial
aim
prevent
progress
uri
lrd
purpos
studi
examin
season
hmpv
infect
hct
recipi
identifi
patient
transplant
viral
risk
factor
progress
lrd
retrospect
cohort
studi
includ
patient
underw
transplant
march
april
fred
hutchinson
cancer
research
center
fhcrc
document
hmpv
infect
pretranspl
condit
transplant
individu
first
episod
hmpv
infect
analyz
patient
demograph
data
transplant
inform
retriev
fhcrc
databas
data
relat
clinic
cours
hmpv
infect
collect
medic
record
review
data
hmpv
infect
commun
base
univers
washington
molecular
virolog
laboratori
data
includ
data
seattl
children
hospit
sampl
sent
laboratori
region
provid
http
deptswashingtonedurspvirusrespiratoryhtm
studi
approv
fhcrc
institut
review
board
nasopharyng
sampl
collect
hct
recipi
uri
symptom
also
collect
bronchoalveolar
lavag
bal
sampl
patient
lower
respiratori
tract
symptom
radiograph
abnorm
followup
nasopharyng
sampl
obtain
subset
patient
initi
appli
direct
fluoresc
antibodi
test
individu
revers
transcript
polymeras
chain
reaction
rtpcr
assay
detect
hmpv
start
multiplex
pcr
test
sampl
consid
posit
pcr
amplif
plot
cross
threshold
cycl
viral
load
determin
quantit
rtpcr
use
nasopharyng
sampl
diagnosi
uri
uri
defin
hmpv
detect
nasopharyng
sampl
uri
symptom
rhinorrhea
stuffi
nose
sore
throat
lrd
defin
detect
hmpv
bal
lung
biopsi
sampl
new
pulmonari
infiltr
detect
radiograph
studi
analog
previou
articl
parainfluenza
viru
lrd
manifest
term
proven
lrd
possibl
lrd
defin
viral
detect
nasopharyng
sampl
new
pulmonari
infiltr
without
bronchoscop
examin
case
includ
uri
studi
patient
diagnos
lrd
day
uri
diagnosi
consid
progress
lrd
durat
viral
shed
defin
day
first
last
date
hmpv
detect
copathogen
defin
signific
pathogen
detect
concurr
respiratori
sampl
blood
sampl
obtain
within
day
diagnosi
hmpv
infect
coagulaseneg
staphylococc
bacteremia
cytomegaloviru
viremia
antigenemia
consid
signific
copathogen
peak
steroid
dose
diagnosi
record
period
within
week
patient
demograph
characterist
compar
among
diseas
categori
use
fisher
exact
test
categor
variabl
wilcoxon
ranksum
test
continu
variabl
appropri
probabl
progress
lrd
among
patient
present
uri
estim
cumul
incid
curv
treat
death
compet
risk
cox
proport
hazard
model
use
evalu
unadjust
adjust
hazard
ratio
progress
lrd
logist
regress
model
use
evalu
crosssect
associ
risk
factor
occurr
lrd
among
patient
includ
patient
present
lrd
risk
factor
durat
shed
assess
use
linear
regress
rank
day
shed
day
twosid
p
valu
consid
statist
signific
statist
analys
perform
use
sa
version
window
sa
institut
cari
north
carolina
hmpv
detect
hct
recipi
uri
alon
lrd
respect
characterist
hmpv
infect
group
shown
tabl
median
time
hmpv
detect
hct
day
rang
day
median
viral
load
nasal
wash
sampl
copiesml
rang
copi
ml
median
day
engraft
day
rang
day
patient
engraft
prior
death
lrd
document
day
hct
earlier
transplant
year
hmpv
infect
sooner
hct
copathogen
low
monocyt
count
observ
frequent
lrd
case
urionli
case
possibl
lrd
case
receiv
transplant
respect
respiratori
viral
copathogen
rhinoviru
n
coronavirus
n
parainfluenza
viru
n
occasion
detect
nasopharyng
bal
sampl
nonvir
copathogen
bal
includ
pseudomona
aeruginosa
n
aspergillu
fumigatu
n
four
patient
bacteremia
due
stenotrophomona
maltophilia
acinetobact
baumannii
enterococcu
faecium
streptococcu
pneumonia
diagnosi
number
hmpv
infect
month
juli
june
shown
figur
infect
identifi
decemb
may
calendar
year
incid
hmpv
infect
hct
recipi
similar
commun
base
univers
washington
refer
laboratori
data
figur
number
hmpv
case
year
shown
figur
hmpv
infect
frequent
detect
lrd
occur
frequent
figur
among
patient
hmpv
lrd
detect
hmpv
uri
diagnosi
lrd
progress
lrd
median
day
rang
day
uri
total
among
patient
uri
probabl
progress
lrd
within
day
figur
approxim
patient
uri
progress
lrd
within
week
uri
univari
cox
model
factor
shown
tabl
use
identifi
risk
factor
progress
lrd
among
patient
present
uri
earli
hmpv
infect
hct
low
lymphocyt
count
steroid
use
mgkg
diagnosi
significantli
associ
diseas
progress
tabl
steroid
dose
remain
signific
one
bivari
model
tabl
probabl
progress
lrd
factor
shown
figur
approxim
hct
recipi
low
lymphocyt
count
steroid
use
mgkg
virolog
diagnosi
subsequ
progress
lrd
univari
logist
regress
model
among
patient
factor
associ
develop
lrd
earli
onset
hmpv
infect
hct
odd
ratio
confid
interv
ci
p
low
lymphocyt
count
ci
p
earlier
transplant
year
ci
p
presenc
copathogen
ci
p
low
monocyt
count
ci
p
use
steroid
mgkg
approach
statist
signific
ci
p
multivari
logist
model
includ
transplant
year
low
lymphocyt
count
high
steroid
use
diagnosi
earlier
transplant
year
adjust
aor
ci
p
low
lymphocyt
count
aor
ci
p
remain
statist
signific
earli
onset
transplant
includ
model
lymphocytopenia
longer
signific
wherea
earli
onset
remain
signific
aor
ci
p
thirtynin
patient
continu
hmpv
detect
day
patient
die
day
prolong
shed
patient
die
day
day
shed
anoth
die
day
day
shed
bivari
analysi
risk
factor
durat
shed
includ
variabl
tabl
steroid
use
mgkg
associ
longer
shed
p
among
patient
detect
virus
nasal
wash
sampl
compar
diseas
statu
viral
load
evid
correl
diseas
statu
viral
load
nasal
wash
sampl
present
data
shown
studi
demonstr
low
lymphocyt
count
steroid
use
mgkg
time
uri
diagnosi
associ
increas
risk
progress
lrd
progress
rate
approach
patient
highestrisk
categori
viral
load
nasopharyng
sampl
time
hmpv
uri
diagnos
appear
predict
risk
progress
lrd
hmpv
rel
newli
discov
respiratori
pathogen
effect
hmpv
infect
hct
recipi
poorli
understood
numer
studi
respiratori
diseas
due
rsv
genet
similar
respiratori
viru
transplant
recipi
report
progress
rate
lrd
mortal
lrd
rang
respect
due
high
incid
rsvrelat
lrd
subsequ
high
mortal
rsv
infect
rsv
infect
hct
consid
import
complic
mortal
follow
hmpv
compar
high
seen
rsv
rate
approxim
hmpv
difficult
diagnos
cultur
method
sever
multiplex
pcr
platform
avail
permit
rapid
sensit
specif
detect
hmpv
progress
rate
lrd
may
affect
underli
condit
hct
recipi
identifi
steroid
use
mgkg
diagnosi
low
lymphocyt
count
onset
hmpv
infect
first
month
hct
import
risk
factor
progress
shown
figur
patient
steroid
use
mgkg
low
lymphocyt
count
progress
characterist
gener
associ
high
mortal
lrd
respiratori
viru
logist
regress
model
provid
addit
insight
lymphopenia
import
lost
signific
time
transplant
includ
suggest
host
defens
mechan
earli
time
period
transplant
monocyt
also
import
event
lrd
unabl
fit
model
includ
factor
potenti
import
diseas
progress
follow
infect
rsv
viru
genet
similar
hmpv
relat
patient
characterist
includ
neutropenia
lymphocytopenia
unrel
donor
statu
condit
includ
total
bodi
irradi
fungal
coinfect
smoke
histori
studi
howev
none
factor
except
lymphocytopenia
associ
progress
although
collect
data
smoke
histori
evalu
pulmonari
function
prior
hmpv
infect
associ
pulmonari
dysfunct
progress
hmpv
infect
detect
improv
patient
outcom
hmpv
infect
strategi
need
develop
prevent
progress
lrd
studi
identifi
highrisk
clinic
situat
earli
intervent
strategi
could
studi
date
proven
effect
treatment
hmpv
infect
sever
small
report
support
use
ribavirin
without
intraven
immunoglobulin
ivig
hmpv
infect
larger
studi
howev
show
protect
effect
ribavirin
hmpv
lrd
studi
nonrandom
studi
mainten
dose
ivig
associ
lower
progress
rate
data
shown
unabl
analyz
effect
ribavirin
highdos
ivig
number
patient
receiv
progress
low
base
find
reduct
steroid
dose
patient
receiv
highdos
steroid
may
possibl
strategi
howev
whether
approach
would
effect
determin
studi
import
find
studi
steroid
use
mgkg
diagnosi
associ
longer
viral
shed
viral
load
nasopharyng
sampl
correl
progress
lrd
effect
viral
load
may
fail
show
relationship
due
issu
relat
host
immun
function
quantifi
studi
gener
perform
nasopharyng
test
patient
uri
symptom
although
uri
symptom
base
host
immun
respons
level
immun
respons
hct
recipi
may
correl
viral
load
anoth
possibl
reason
progress
pneumonia
may
relat
viral
load
upper
respiratori
tract
previou
studi
parainfluenza
viru
pathogen
detect
patient
idiopath
pneumonia
syndrom
hct
fail
show
associ
viral
load
bal
sampl
level
lung
injuri
outcom
consist
find
current
studi
although
demonstr
correl
viral
load
progress
lrd
possibl
larger
studi
standard
bal
viral
load
measur
control
dilut
may
improv
understand
role
viral
load
diseas
progress
studi
sever
limit
although
cohort
repres
largest
number
hct
recipi
infect
hmpv
receiv
quantit
virolog
workup
upper
lower
respiratori
tract
sampl
sampl
size
small
definit
assess
patient
characterist
studi
role
individu
copathogen
also
enough
event
multivari
analys
nevertheless
abl
perform
sever
differ
bivari
cox
model
anoth
limit
long
observ
period
variou
transplant
procedur
chang
low
lymphocyt
count
steroid
dose
diagnosi
import
factor
progress
lrd
reduc
intens
condit
regimen
relat
mild
lymphocytopenia
frequent
use
center
recent
adopt
lower
dose
steroid
initi
treatment
acut
graftvshost
diseas
may
affect
incid
lrd
recent
year
although
includ
possibl
factor
affect
progress
rate
analys
may
miss
import
factor
chang
studi
period
main
method
detect
hmpv
also
chang
long
observ
period
howev
appar
bia
way
sampl
collect
test
perform
bronchoscopi
patient
lower
respiratori
tract
symptom
radiograph
abnorm
nevertheless
final
decis
left
attend
physician
therefor
aggress
workup
declin
possibl
lrd
case
especi
case
late
hct
may
result
underreport
progress
lrd
case
virolog
analys
also
limit
inconsist
surveil
viral
shed
incomplet
ascertain
viral
load
dilut
factor
nasal
wash
sampl
although
previou
studi
suggest
dilut
effect
rather
limit
conclus
find
show
hmpv
infect
hct
recipi
occur
primarili
winter
spring
progress
rate
uri
lrd
approach
patient
acquir
hmpv
infect
low
lymphocyt
count
use
mgkg
steroid
prior
uri
data
provid
necessari
foundat
design
clinic
trial
studi
efficaci
new
antivir
compound
urgent
need
studi
need
defin
role
viral
load
pathogenesi
progress
diseas
cumul
incid
progress
lrd
day
hematopoiet
cell
transplant
hct
diagnosi
uri
global
p
logrank
test
b
cumul
incid
progress
lrd
lymphocyt
count
global
p
c
cumul
incid
progress
lrd
steroid
dose
diagnosi
uri
global
p
